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Abstract
NF-E2 related factor-2 (Nrf2) promotes the transcription of many cytoprotective genes and is a major drug target for
prevention of cancer and other diseases. Indeed, the cancer-preventive activities of several well-known chemical agents
were shown to depend on Nrf2 activation. It is well known that chemopreventive Nrf2 activators stabilize Nrf2 by blocking
its ubiquitination, but previous studies have indicated that this process occurs exclusively in the cytoplasm. Kelch-like ECH-
associated protein 1 (Keap1) binds to Nrf2 and orchestrates Nrf2 ubiquitination, and it has been a widely-held view that
inhibition of Nrf2 ubiquitination by chemopreventive agents results from the dissociation of Nrf2 from its repressor Keap1.
Here, we show that while the activation of Nrf2 by prototypical chemical activators, including 5,6-dihydrocyclopenta-1,2-
dithiole-3-thione (CPDT) and sulforaphane (SF), results solely from inhibition of its ubiquitination, such inhibition occurs
predominantly in the nucleus. Moreover, the Nrf2 activators promote Nrf2 association with Keap1, rather than
disassociation, which appears to result from inhibition of Nrf2 phosphorylation at Ser40. Available evidence suggests the
Nrf2 activators may block Nrf2 ubiquitination by altering Keap1 conformation via reaction with the thiols of specific Keap1
cysteines. We further show that while the inhibitory effects of CPDT and SF on Nrf2 ubiquitination depend entirely on
Keap1, Nrf2 is also degraded by a Keap1-independent mechanism. These findings provide significant new insight about Nrf2
activation and suggest that exogenous chemical activators of Nrf2 enter the nucleus to exert most of their inhibitory impact
on Nrf2 ubiquitination and degradation.
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Introduction
Nrf2 has emerged as a ubiquitous transcription factor that plays
a critical role in the maintenance of cellular homeostasis. It
stimulates the transcription of genes involved in many aspects of
cytoprotection, most notably the Phase 2 genes, e.g., glutamate
cysteine lygase (GCS) and NAD(P)H:quinone oxidoreductase-1
(NQO1). Indeed, Nrf2 knockout mice showed significantly
increased susceptibility to a variety of diseases, such as cancer
[1,2], neurodegeneration [3] and inflammation [4,5]. Nrf2 works
by binding as a heterodimer with Maf or other partners to a cis-
acting DNA regulatory element, namely the antioxidant response
element (ARE), which is located in the upstream region of the
target genes, stimulating gene transcription. Nrf2 is activated itself
by many chemopreventive agents and is essential for some of these
agents to prevent cancer and other diseases in animal models
[1,2,6]. Consequently, pharmacological activation of Nrf2 has
been widely advocated as a major strategy for prevention of cancer
and other diseases [7,8]. Interestingly, recent studies have also
shown that Nrf2 may be upregulated in cancer cells and that the
cytoprotective function of Nrf2 may contribute to the survival and
growth of cancer cells, suggesting that it may be important to
inhibit Nrf2 during cancer chemotherapy [9].
However, the mechanism by which chemopreventive agents
activate Nrf2 remains less understood. While most studies have
indicated that chemopreventive agents activate Nrf2 by blocking
its degradation at the protein level, there are also studies
suggesting that nrf2 gene transcription may be stimulated
[10,11]. Nrf2 protein upon synthesis is rapidly degraded by the
26S proteasome in unstimulated cells (half-life of approximately
15 min) [12,13]. Keap1, also known as the Nrf2 repressor, is
crucial for the rapid turnover of Nrf2 and functions as an adaptor
for Nrf2 ubiquitination at the lysine residues of the Neh2 domain
by a Cul-3-dependent ubiquitin ligase complex [14,15]. Chemical
binding or oxidation of specific reactive cysteine residues of Keap1
disrupts Keap1-mediated Nrf2 ubiquitination and results in Nrf2
accumulation/activation, which in turn leads to increased
transcription of ARE-regulated genes and increased cytoprotec-
tion [16]. However, there are conflicting views as to how chemical
agents block Nrf2 ubiquitination. While it has been widely
believed that reaction of Nrf2 activators with critical cysteine
residues of Keap1 causes it to free Nrf2, thereby stabilizing Nrf2
[13,17,18], there are also studies suggesting that chemical
modification of Keap1 cysteines is not sufficient to disrupt Nrf2
binding to Keap1 [19–21], and other studies report that Nrf2
phosphorylation (at Ser40) by protein kinase C or transmembrane
protein kinase PERK promotes its dissociation from Keap1 [22–
24]. Moreover, it has also been reported that chemical
modification of Keap1 cysteines may trigger its own ubiquitination
and degradation, freeing Nrf2 from degradation [25]. Uncertainty
also exists as to where in the cell chemical activators inhibit Nrf2
degradation. The prevailing view has been that inhibition of
Keap1-mediated Nrf2 ubiquitination and degradation occurs
exclusively in the cytoplasm [16,26,27], but Nrf2 was shown to
be primarily a nuclear protein [28].
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mechanism of chemical activation of Nrf2. The study was carried
out in multiple human and animal cell lines, utilizing CPDT and
SF as prototypical Nrf2 activators. Both CPDT and SF (see
Figure 1A for their chemical structures) are well-known
chemopreventive agents and represent two major classes of
chemopreventive Nrf2 activators: dithiolethiones and isothiocya-
nates [29–31]. We show that both CPDT and SF rapidly elevated
Nrf2 protein, which was accompanied by increased Nrf2
transactivation activity, but did not modulate nrf2 gene transcrip-
tion and Keap1 protein expression. We further show that CPDT
and SF inhibited Keap1-dependent Nrf2 ubiquitination, but Nrf2
was also degraded via a Keap1-independent pathway. Neither
CPDT nor SF disassociated the Nrf2-Keap1 complex or disrupted
the ubiquitin ligase complex, but both compounds inhibited Nrf2
phosphorylation, which may account for the sustained association
of Nrf2 with Keap1. Moreover, we demonstrate that the
machinery for Nrf2 ubiquitination and proteasomal degradation
exists in both cytoplasm and nucleus but that inhibition of Nrf2
ubiquitination by CPDT and SF occurs primarily in the nucleus,
rather than in the cytoplasm. These findings significantly advance
our understanding about the mechanism of Nrf2 activation and
also have important implication for the development of Nrf2-
based chemopreventive strategies. Our data indicate for the first
time that Nrf2 chemopreventive agents enter the nucleus to inhibit
nuclear Nrf2 ubiquitination.
Results
CPDT and SF stabilize Nrf2 protein and inhibit its
phosphorylation
Both CPDT and SF rapidly elevated Nrf2 protein in RT-4 cells
(a human bladder cancer cell line) and NBT-II cells (a rat bladder
cancer cell line) (Figure 1B). Maximal elevation of Nrf2 appears
to be reached in both cell lines after 6 h treatment with each
agent. A preliminary experiment showed that both agents caused
dose-dependent elevation of Nrf2; their optimal concentrations
(CPDT at 50 mM and SF at 8 mM) were used in the experiments
reported herein. Neither agent had any impact on Nrf2 mRNA
level (Fig. 1C), indicating that nrf2 gene transcription or its
message stability was not affected by the compounds. Hence,
CPDT and SF stabilized Nrf2 protein. Although a previous study
suggested that Nrf2 activators might stabilize Nrf2 by increasing
the ubiquitination and proteasomal degradation of Keap1 [25], we
did not find that increased Nrf2 stability in response to CPDT and
SF was associated with Keap1 degradation, as Keap1 remained
essentially unchanged in cells treated by CPDT or SF (Figure 1C),
Two Keap1 bands were detected in RT-4 cells, but only one in
NBT-II cells. The exact reason for the doublet is not known, but
such doublet was also detected in cells after transient transfection
of a Keap1-expressing plasmid (Figure 2C) and was apparently
present in other cells [26]. Previous studies have shown that Nrf2
phosphorylation at Ser40 is necessary for Nrf2 to dissociate from
Keap1 and to escape Keap1-mediated ubiquitination [22–24].
While p-Nrf2 (p-Ser40) was readily detected in both cell lines when
un-stimulated, it changed minimally at 6 h and decreased at 24 h
after treatment with CPDT or SF, in contrast to the marked
increase in total Nrf2 level (Figure 1B). Likewise, p-Nrf2 level did
not change in either the cytoplasm or the nucleus, despite marked
increase in Nrf2 level in both compartments in response to CPDT
and SF (Figure 3A). Thus, both compounds are highly effective
inhibitors of Nrf2 phosphorylation. This also ruled out the
possibility that Nrf2 stabilization by CPDT and SF was due to
phosphorylation-induced escape of Nrf2 from Keap1.
As expected, Nrf2 elevation by CPDT and SF was accompanied
by significantly increased expression of GCS (heavy subunit) and
NOQ1 (Figure 1B), both of which are Nrf2 target genes and were
measured to assess Nrf2 transactivation activity. Likewise, in cells
stably transfected with a Nrf2 reporter construct, both CPDT and
SF significantly stimulated the reporter expression (Figure S1).
Nrf2 is degraded through both Keap1-dependent and –
independent pathways, but CPDT and SF only block
Keap1-dependent Nrf2 degradation
As expected, Keap1 knockout in murine embryonic fibroblasts
(MEF) or Keap1 knockdown by siRNA in RT-4 cells resulted in
increased expression of Nrf2 (Figure 2A and Figure 2B).
Treatment of MEF/Keap1
+/+ cells or RT-4 cells (pretreated with
control siRNA) with either CPDT (50 mM) or SF (8 mM) for 6 h
led to significant elevation of Nrf2 protein. In contrast, the
inductive effects of CPDT and SF were either absent in MEF/
Keap1
2/2 or greatly attenuated in RT-4 cells with Nrf2
knockdown (Figure 2A and Figure 2B). However, after
treatment with MG132 (25 mM, 6 h), a specific proteasome
inhibitor, Nrf2 was significantly elevated in both cell lines,
regardless of Keap1 status (Figure 2A and Figure 2B). Similar
results were obtained with epoxomicin, another specific protea-
some inhibitor (result not shown). These results reveal that Nrf2 is
degraded through both Keap1-dependent and Keap1-indepen-
dent proteasomal pathways, but both CPDT and SF only block
Keap1-mediated Nrf2 degradation.
Figure 1. CPDT and SF stimulate Nrf2 transactivation activity
by stabilizing its protein. (A) Chemical structure of CPDT and SF. RT-
4 cells and NBT-II cells were treated with CPDT (50 mM), SF (8 mM) or
vehicle (0.1% DMSO) for 6 or 24 h. (B) Whole cell lysates were then
prepared for IB or (C) total RNA was isolated for RT-PCR analysis.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a
control.
doi:10.1371/journal.pone.0035122.g001
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(C273 and C288) to be critical for Nrf2 stabilization by chemical
activators [17,32]. To confirm that Nrf2 stabilization by CPDT
and SF requires these cysteines, MEF with double knockout of
Keap1 and Nrf2 were transfected with a Nrf2 expression vector
with or without a Keap1 expression vector for 48 h, followed by
treatment with CPDT (50 mM) or SF (8 mM) for 6 h. Wild type
Keap1 and three Keap1 mutants (the cysteine at 257, 273 or 288
was replaced with a serine) were tested. The C257S mutant was
included as a control. Similar Keap1 expression levels were
detected after transfection of each of the four Keap1 vectors
(Figure 2B). As expected, both wild type Keap1 and the C257S
mutant significantly reduced Nrf2 level, whereas both C273S and
C288S mutants failed to do so. The point mutations did not affect
the association of Keap1 with Nrf2 (Figure S2). Moreover, both
CPDT and SF prevented wild type Keap1 and the C257S mutant
from reducing Nrf2, but their effects on Nrf2 in cells transfected
with either the C273S mutant or the C288S mutant were
marginal. Given that both C273 and C288 were previously shown
to be directly bound by dexamethasone 21-mesylate, a Nrf2
activator, through chemical reaction with the thiol groups [18]
and that both CPDT and SF are thiol-reactive, there is little doubt
that direct binding to the thiol groups of C723 and C288 of Keap1
by CPDT and SF leads to stabilization of Nrf2.
CPDT and SF stabilize Nrf2 predominantly in the nucleus
and do not disrupt Keap1-Nrf2 association
Contrary to the wide-spread belief that inhibition of Nrf2
degradation by Nrf2 activators occurs exclusively in the cytoplasm,
our experiments showed that inhibition of Nrf2 degradation by
both CPDT and SF took place predominantly in the nucleus, as
described below. Cytoplasmic and nuclear fractions were carefully
prepared from both RT-4 cells and NBT-II cells after treatment
with CPDT (50 mM) or SF (8 mM) for 6 h. No cross-contamina-
tion was detected, as the nuclear marker lamin A was not detected
in the cytoplasmic fraction and the cytoplasmic marker GAPDH
was not detected in the nuclear fraction (Figure 3A). Marked Nrf2
accumulation was detected in the nucleus in both cell lines after
treatment with each compound, whereas increase in cytoplasmic
Figure 2. CPDT and SF block only Keap1-mediated Nrf2
degradation and require key cysteine residues of Keap1. (A)
Murine embryonic fibroblasts (MEF), including wild type MEF (Keap1
+/+)
and MEF with Keap1 knockout (Keap1
2/2), were treated with vehicle,
MG132 (25 mM), CPDT (50 mM) or SF (8 mM) for 6 h. Cells were then
harvested for IB of Nrf2 and GAPDH. (B) RT-4 cells were transfected with
either a control siRNA or a specific Keap1-targeting siRNA for 48 h,
followed by treatment with vehicle, MG132 (25 mM), CPDT (50 mM) or SF
(8 mM) for 6 h. Cells were then harvested for IB of Nrf2, Keap1 and
GAPDH. (C) MEF with knockout of both Keap1 and Nrf2 were mock
transfected or transfected with expression vectors of Nrf2 (pEF/Nrf2)
[42] with or without Keap1 (wild type or one of three Keap1 mutants, all
cloned to pcDNA3) [32] for 48 h, followed by treatment with vehicle,
CPDT (50 mM) or SF (8 mM) for 6 h. Whole cell lysates were then
prepared for IB.
doi:10.1371/journal.pone.0035122.g002
Figure 3. CPDT and SF block Nrf2 degradation mainly in the
nucleus, but do not dissociate the Nrf2-Keap1 complex or the
ubiquitination complex. RT-4 cells and NBT-II cells were treated with
vehicle, CPDT (50 mM) or SF (8 mM) for 6 h, from which cytosols and
nuclear extracts were prepared and were subjected to analysis by IB or
IP followed by IB. The loading amount of the nuclear sample was about
half of the cytoplasmic sample for both IP and IB. (A) IB of indicated
proteins. GAPDH and lamin A were used to confirm the purity of the
cytosols and nuclear extracts, respectively. (B) Cytosols and nuclear
extracts were subjected to IP with anti-Keap1, followed by IB of the
indicated proteins.
doi:10.1371/journal.pone.0035122.g003
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protein was used for the cytosolic samples, compared to the
nuclear samples, in the experiment shown in Fig. 3. Keap1 protein
was detected in both cytoplasm and nucleus, but neither CPDT
nor SF had any effect on its expression level, consistent with our
result from the whole cell lysates (Figure 1A).
Using IP with anti-Keap1, followed by immunoblotting (IB)
with anti-Keap1 or anti-Nrf2, we again found that neither CPDT
nor SF had any effect on Keap1 protein level either in the
cytoplasm or in the nucleus in both cell lines, but both agents
significantly increased the Keap1-Nrf2 complex, mainly in the
nucleus (Figure 3B). Comparison of the total levels of Nrf2 and
Keap1 (Figure 3A) with their levels in the Keap1-Nrf2 complex
(Figure 3B) suggests that most if not all of the Nrf2 molecules that
were elevated by CPDT and SF were associated with Keap1.
These results challenge the existing theory that Nrf2 activators
stabilize Nrf2 protein by freeing it from Keap1 or by stimulating
the degradation of Keap1. Increased association of Nrf2 with
Keap1, induced by CPDT and SF, was not accompanied by
corresponding increase in Nrf2 phosphorylation at Ser40
(Figure 1B and Figure 3A), indicating that Nrf2 phosphorylation
was inhibited by these compounds in both cytoplasm and nucleus.
Phosphorylation at this site was previously shown to be required
for Nrf2 release from Keap1 [22–24].
CPDT and SF inhibit Nrf2 ubiquitination in both
cytoplasm and nucleus but do not disassociate the
ubiquitin ligase complex
Cellular level of ubiquitinated Nrf2 was not detectable under
basal conditions, with or without treatment by CPDT or SF. Thus,
cells were co-transfected with three plasmids (plasmids expressing
Nrf2, Keap1 and His-tagged ubiquitin) for 24 h, followed by
treatment with CPDT or SF for 6 h in the presence of MG132 (to
inhibit degradation of ubiquitinated Nrf2), from which both
cytosolic and nuclear fractions were prepared. We focused on
NBT-II cells, because ectopic expression of ubiquitin (Ub) in RT-4
cells was extremely poor. IB analysis showed that sample
preparation was satisfactory, as the cytoplasmic protein GAPDH
was not detected in the nuclear samples and the nuclear protein
lamin A was not detected in the cytosolic samples (Figure 4).
Treatment of NBT-II cells with the three plasmids and MG-132
significantly increased Nrf2 levels in both cytoplasmic and nuclear
fractions, and CPDT and SF elevated Nrf2 level further. Keap1
levels in both cytoplasm and nucleus were increased after plasmid
transfection and treatment with MG132, but neither CPDT nor
SF showed any effect on Keap1. While Ub expression was not
affected by CPDT and SF either, ectopic Ub expression was
markedly higher in the cytoplasm than in the nucleus (Figure 4).
Next, ubiquitinated Nrf2 was measured by IP with an anti-Nrf2
antibody and IB with a His-HRP conjugated antibody (detecting
the His tag of Ub). In cells transfected with the triple plasmids and
treated with MG132, ubiquitinated Nrf2 was detected in both the
cytoplasm and the nucleus, but its level in the nucleus was much
lower than in the cytosol, apparently due to the fact that
ectopically expressed Ub existed predominantly in the cytosol
(Figure 4). However, both CPDT and SF markedly inhibited
Nrf2 ubiquitination in both the cytoplasm and the nucleus.
We next asked how CPDT and SF prevented Keap1 from
promoting Nrf2 ubiquitination. It has been previously shown that
Keap1 and Nrf2 form a ubiquitin ligase core complex with Cul3
and Rbx1 in the cytoplasm [15]. However, all four proteins were
detected in the cytoplasm and nucleus of both RT-4 cells and
NBT-II cells, and neither CPDT nor SF had any effect on the
expression of Keap1, Cul3 and Rbx1 in both compartments
(Figure 3A). Moreover, in experiments involving IP with anti-
Keap1, followed by IB with respective antibodies, neither CPDT
nor SF disrupted the association of Keap1 with Cul3 and Rbx1 in
either cytoplasm or nucleus, while Nrf2 level in the complex
increased significantly, especially in the nucleus (Figure 3B).
These results show that a Nrf2 ubiquitination-proteasome
degradation system is present in both cytoplasm and nucleus,
and that inhibition of Nrf2 ubiquitination by CPDT and SF does
not result from the disassociation of the ubiquitination core
complex.
Discussion
In the present study, CPDT and SF were used as probes to
understand the mechanism of chemical activation of Nrf2. CPDT
and SF belong to two well-known classes of Nrf2 activators -
dithiolethione and isothiocyanate, many of which are being
investigated for prevention of cancer and other diseases. The
chemopreventive activity of SF, which occurs in broccoli and other
plants is particularly promising [30]. We show that both CPDT
and SF markedly elevate Nrf2 protein level and stimulate Nrf2
transactivation activity in human, mouse and rat cell lines
(Figures 1,2,3). Similar results were previously shown in other
cell lines [33,34]. Thus, the effects of CPDT and SF on Nrf2 are
neither cell line-specific nor species-specific. Neither agent showed
Figure 4. CPDT and SF block Nrf2 ubiquitination. NBT-II cells
were co-transfected for 24 h with expression plasmids for Nrf2 (pEF/
Nrf2), Keap1 (pcDNA1/Keap1) or ubiquitin (pMT107-His-Ub, a poly-
histidine-tagged ubiquitin expression plasmid), followed by treatment
for 6 h with MG132 (25 mM), MG132 (25 mM) plus CPDT (50 mM), or
MG132 (25 mM) plus SF (8 mM), from which cytoplasmic and nuclear
samples were prepared and analyzed by IB of various proteins. For
detection of ubiquitinated Nrf2, the samples were prepared under
denatured conditions and then subjected to IP with anti-Nrf2, followed
by IB with an anti-His-HRP-conjugated antibody (for detection of
ubiquitinated Nrf2). Equal amounts of nuclear and cytoplasmic proteins
were used. The arrow points to the Ub band.
doi:10.1371/journal.pone.0035122.g004
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expression. Thus, the activities of these agents also fit with the
widely accepted view that chemopreventive agents generally
activate Nrf2 by blocking its protein degradation. Based on these
considerations, CPDT and SF may be viewed as prototypical Nrf2
activators. It should be noted, however, that in all of our
experiments, the Nrf2 band was detected at ,100 kD, although
the expected molecular weight of Nrf2 is ,68 kD. The exact
reason is not known, but this phenomenon has been previously
reported and may be related to a Nrf2-actin complex [35,36].
Keap1 promotes proteasomal degradation of Nrf2 by orches-
trating Nrf2 ubiquitination. As expected, we found that Keap1
knockout or knockdown caused significant increase in Nrf2 level,
whereas forced expression of Keap1 reduced Nrf2 expression
(Figure 2). Both CPDT and SF significantly elevated Nrf2 levels
in Keap1-present cells, but such effect was completely lost in
Keap1-knockout cells or greatly attenuated in cells whose Keap1
was knocked down by siRNA (Figure 2). Hence, the Nrf2-
elevating ability of CPDT and SF depends on Keap1. This
information has a practical implication in the design of
chemopreventive strategies. Hayes and coworkers previously
suggested that Keap1 knockdown with RNAi might be a
potentially useful strategy for cancer chemoprevention [37].
Clearly, such a strategy cannot be combined with CPDT, SF or
similar agents, since the ability of the latter to activate Nrf2
depends on Keap1. However, we have shown in this study that
Nrf2 protein is degraded through both Keap1-dependent and
Keap1-independent proteasomal pathways. At the present time,
little is known about Keap1-independent proteasomal degradation
of Nrf2.
Both CPDT and SF inhibited Nrf2 ubiquitination in both
cytoplasm and nucleus (Figure 4). While Keap1 associates with
Cul3 and Rbx1 to form a functional E3 ubiquitin ligase core
complex, which ubiquinates Keap1-bound Nrf2 and targets it for
degradation by 26S proteasome [14,20], neither CPDT nor SF
dissociates the ubiquitination core complex or alter the expression
of each protein (Figure 3). Moreover, our data clearly show that
the Nrf2-ubiquinating complex exists in both cytoplasm and
nucleus and that inhibition of Nrf2 ubiquitination by CPDT and
SF occurs primarily in the nucleus (Figure 3 and Figure 4). It is
of note that the 26S proteasome has been shown to exist in both
cytoplasm and nucleus [38]. In contrast, a previous report
indicated that Nrf2 was ubiquitinated and degraded only in the
cytoplasm [26]. The reason for such a discrepancy is not entirely
clear, but may be related to experimental conditions. We have
found that forced overexpression of Keap1, Nrf2 and Ub in
cultured cells, which was used in the previous study mentioned
above, could generate misleading results, as ectopically expressed
Keap1 and Nrf2 existed largely in the cytoplasm in MEF (Figure
S2) and ectopically expressed Ub existed largely in the cytoplasm
in NBT-II cells (Figure 4). We have also shown that inhibition of
Nrf2 ubiqutination by CPDT or SF does not result from Nrf2
release from Keap1; rather, both agents prevent Nrf2 from leaving
Keap1 (Figure 3). This also directly contrasts with the widely-
accepted model that chemical activation of Nrf2 results from
dissociation of Nrf2 from Keap1, thereby allowing Nrf2 to escape
Keap1-mediated proteasomal degradation. It is particularly
surprising that the Keap1-Nrf2 dissociation model was based in
part on studies involving SF [18]. The reason for the discrepancy is
not entirely known, but a close examination of the previous studies
that led to the Keap1-Nrf2 dissociation model revealed that key
experiments were performed in cell-free systems [18,26]. In
addition, our present study also appears to have uncovered the
potential mechanism by which CPDT and SF prevent Nrf2 release
from Keap1. Both CPDT and SF strongly inhibited Nrf2
phosphorylation at Ser40 (Figure 1B and Figure 3A). It was
previously shown that phosphorylation at this site is required for
Nrf2 release from Keap1 [22–24]. However, it is not yet known if
CPDT and SF inhibit the phosphorylation of and/or stimulate the
dephosphorylation of Nrf2. A putative nucleocytoplasmic shuttling
system of Keap1/Nrf2 has been previously reported [26], but
neither CPDT nor SF had any effect on Keap1 level in either the
cytoplasm or the nucleus of RT4 cells and NBT-II cells (Figure 3),
implying that this shuttle system was not involved in CPDT- and
SF-induced increase in nuclear Nrf2. A previous study also found
that compounds such as diethyl maleate and butylated hydro-
xyanisole promoted nuclear accumulation of Nrf2 without altering
the subcellular localization of Keap1 [27].
In summary, both CPDT and SF inhibit Keap1-mediated Nrf2
ubiquitination, and such inhibition occurs mainly in the nucleus
(Figure 5). Neither agent disrupts the association of the Nrf2-
ubiquitinating core complex, nor do they free Nrf2 from Keap1 or
affect the potential nucleocytoplasmic shuttling of Keap1/Nrf2.
Cys273 and Cys288 of Keap1 are essential for the Nrf2-stabilizing
activity of CPDT and SF; these cysteines likely undergo
conjugation reaction through their thiol groups with CPDT and
SF or their metabolites. We propose that such reactions cause
conformational change of Keap1 and renders Keap1-bound Nrf2
unreachable by the ubiquitin ligase (Figure 5). Indeed, a previous
study suggests that C273 and C288 of Keap1 function as ligands in
zinc coordination [39]. It is conceivable that modification of these
cysteines by CPDT and SF as well as other Nrf2 activators disrupts
the zinc coordination and thus alters Keap1 conformation.
Materials and Methods
Antibodies and reagents
The antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA), including anti-Nrf2 (sc-722, sc-13032), anti-
GCS (sc-22755, detecting GCS heavy subunit), anti-Keap1 (sc-
15246), anti-lamin A (sc-20680), anti-ubiquitin (sc-8017) and anti-
His-tag (His-probe H3), and from Millipore (Billerica, MA),
including anti-Rbx1 (AB3737) and anti-GAPDH (MAB374).
Other antibodies including anti-NQO1 (3187), anti-p-Nrf2
(2073-1; specifically recognizing phosphorylation at serine 40)
and anti-Cul3 (611848) were purchased from Cell Signaling
(Beverly, MA), Epitomics (Burlingame, CA), BD Biosciences (San
Jose, CA), respectively. An anti-His-HRP-conjugated antibody was
purchased from Qiagen (Valencia, CA). CPDT was provided by
Dr. Rex Munday [32]. SF and epoxomicin were purchased from
LKT Laboratories (St. Paul, MN), and MG132 was purchased
from EMD (Gibbstown, NJ).
Cell culture, chemical treatment, gene knockdown and
gene overexpression
NBT-II cells [33], RT-4 cells [40], MEFs (wild type MEF,
MEF/Keap1
2/2, MEF/Keap1
2/2/Nrf2
2/2) [17] were cultured
in MEM, Iwakata and Grace’s modified McCoy’s 5A, and Iscove’s
modified DMEM, respectively, at 37uC and 5% CO2. All media
were supplemented with 10% FBS. For treatment with the test
agents, cells were seeded in 10-cm dishes (1–2610
6 cells/10 ml
medium/dish) or 6-well plates (0.25610
6 cells/2 ml medium/well)
overnight and then treated with a test agent for a desired time
before harvest by trypsin treatment and low-speed centrifugation
at 4uC. All agents were dissolved in DMSO, and the final DMSO
concentration in the media was ,0.25% (v/v). To knock down
Keap1, cells were transfected with Keap1 stealth RNAi
(HSS190639) or a universal control stealth RNAi (12935300)
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following the manufacturer’s protocol. For gene overexpression,
cells were transfected with a desired plasmid (2 mg DNA/well for
MEF or 6 mg DNA/dish for NBT-II cells) for 24–48 h, according
to the manufacturer’s recommended protocol for plasmid
transfection with lipofectamine 2000.
Subcelluar fractionation, immunoprecipitation and
immunoblotting
Cytoplasmic and nuclear fractions were prepared using NE-
PER Nuclear and Cytoplasmic Extraction Reagents Kit (Thermo
Scientific, Waltham, MA), following the manufacturer’s instruc-
tion. For immunoprecipitation (IP), cytosols and nuclear extracts
were incubated with a desired IP antibody, and the immune
complexes were pulled down by incubation with protein A or G
sepharose 4 Fast Flow Beads (GE Healthcare, Piscataway, NY)
and centrifugation. When measuring ubiquitinated Nrf2, the
cytosols and nuclear extracts were denatured first to disrupt
potential association of Nrf2 with other proteins before IP. These
and other samples were electrophoresed on SDS-PAGE and
transferred to polyvinylidene difluoride membranes. The mem-
branes were blocked in TBS-0.05% Tween 20 with 5% non-fat
milk, incubated with primary antibodies, and after extensive wash,
incubated with a peroxidase-conjugated secondary antibody.
Protein bands were visualized using either the Amersham ECL
Plus System (GE Healthcare) or the SuperSignal West Pico
Chemiluminescence Detection System (Thermo Scientific).
RT-PCR
Total RNA was isolated using the Qiagen RNeasy Mini Kit and
Qiagen Qiashredder (Qiagen, Germantown, MD), from which
cDNA was synthesized using random primers and SuperScript II
RT (Invitrogen). PCR primers were as follows: Rat Nrf2, 59-agt
cgc ttg ccc tgg ata ttc-39 and 59- gcc gga gtc aga gtc att gaa-39;
human Nrf2, 59-atg gat ttg att gac ata ctt t-39 and 59- act gag cct
gat tag tag caa t-39; GAPDH, 59- gac cac agt cca tgc cat ca -39 and
59 – tcc acc acc ctg ttg ctg ta- 39. PCR was carried out in a 50 ml
volume and run for 30 cycles in an Eppendorf Mastercycler
Gradient Thermal Cycler (Eppendorf, Hamburg, Germany). The
amplified products were electrophoresed on agarose gel and
stained with ethidium bromide.
Supporting Information
Figure S1 Stimulation of Nrf2 transactivation actvitity
by CPDT and SF. HepG2 cells were stably transfected with
either a Nrf2 reporter construct (ARE-TK-GFP), where the cDNA
coding the green fluorescence protein (GFP) was cloned in tandem
behind the Nrf2-binding element antioxidant response element
(ARE) and the thymidine kinase promoter (TK), or a control
vector (TK-GFP) as previously described [41]. These cells were
cultured in DMEM with 10% FBS and treated with vehicle
(DMSO), CPDT (50 mM) or SF (8 mM) for 24 h. Whole cell lysates
were then prepared to measure the relative GFP level using a
fluorescence spectrometer as previously described [37]. Each value
is a mean 6 SD (n=3). Two sided t-test was used for data analysis.
(TIF)
Figure S2 The effects of CPDT and SF on Keap1-
mediated Nrf2 degradation. Murine embryonic fibroblasts
(MEF) were cultured in Iscove’s modified DMEM. MEF with
knockout of both Keap1 and Nrf2 were co-transfected with
expression vectors of Nrf2 and one of the two Keap1 mutants
(C257S and C273S) for 48 h, followed by treatment with vehicle,
CPDT (50 mM) or SF (8 mM) for 6 h. Both cytosolic fractions and
nuclear fractions were prepared, using the NE-PER Nuclear and
Cytoplasmic Extraction Reagents Kit (Thermo Scientific, Wal-
tham, MA). Cross-contamination was ruled out by IB of b-tubulin
(cytoplasmic marker) and lamin A (nuclear marker). Both fractions
were then subjected to IP by anti-Keap1, followed by IB with anti-
Nrf2 and anti-Keap1.
(TIF)
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Figure 5. The paradigm of chemical activation of Nrf2. The
Keap1-mediated Nrf2 ubiquitination and proteasomal degradation exist
in both cytoplasm and nucleus. Nrf2 activators block Nrf2 ubiquitination
by causing conformational change of Keap1 through reaction with its
critical cysteine residues (C273 and C288), and this process occurs
primarily in the nucleus. Keap1 is shown as a monomer in this model,
but a previous study suggests that Nrf2 may be associated with Keap1
homodimer [43].
doi:10.1371/journal.pone.0035122.g005
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